Transcript NEWS YOU CAN USE 2017 01 UPD

News You Can Use…
Claudia Ortiz Lopez, PharmD Candidate
Kelsy Combs, PharmD
Pete Koval, PharmD
Cone Health Family Medicine
January, 2017
Brand-to-Generic Switch
• Tamiflu® is now available generically as
oseltamivir phosphate
• Generic approved on 8/5/16, now
available from Alvogen
http://www.drugstorenews.com/article/alvogen-natco-launch-first-tamiflu-generic
Health Care Costs
• US Spending on Personal Health care
and Public Health 1996-2013
• Highest Health Care Annual Spending
1. Diabetes $101.4 billion
2. Ischemic Heart Disease $88.1 billion
3. Low Back and Neck Pain $87.6 billion
JAMA. 2016;316(24):2627-2646.
FDA Approval
• MACI (Matrix-induced autologous
chondrocyte implantation)
• First FDA-approved product that uses tissue
engineering to grow cells on scaffolds using
healthy cartilage tissue from the patient’s
own knee
• For the repair of symptomatic, full thickness
cartilage defects of the knee in adult patients
• ADEs: joint pain, cold-like symptoms,
headache, back pain
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533153.htm
Statins in Younger Patients
• New study showed low rates of statin
prescription in younger patients with
severe dyslipidemia (LDL >190 mg/dL)
• Statins prescribed per age group:
• 30-40 yo – 32%
• 40-50 yo – 47%
• 50-60 yo – 61%
Rate of Statin Prescription in Younger Patients With Severe Dyslipidemia. JAMA Cardiol. Published online January 04, 2017.
FDA Labeling Addition
• Jardiance ® (empagliflozin)
• MOA: SGLT2
• FDA adds new indication to reduce
the risk of CV death in adult patients
with type 2 diabetes and CV disease
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm
ADA 2017 update for Diabetes
• Recommendation added to consider
empagliflozin (SGLT2) or liraglutide
(GLP1)
• Median cost of noninsulin and insulin
agents added
• Noninferiority of GLP1 vs rapid acting
insulin vs twice daily premixed insulin in
addition to basal insulin
Diabetes Care 2017;40(Suppl. 1):S4–S5
Diabetes Care 2017;40(Suppl. 1):S64–S74
FDA Approval
• Spinraza® (nusinersen)
• Class: survival motor neuron-2 (SMN2)
directed antisense oligonucleotide
• For the treatment of spinal muscular atrophy
in pediatric and adult pateints
• Dose: 12 mg intrathecally x 4 loading doses
then every 4 months
• ADE: respiratory infection, constipation
http:// http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/100180/spinraza-nusinersen
FDA Approval
• Eucrisa® (crisaborole)
• Class: phosphodiesterase 4 (PDE-4)
inhibitor
• For the treatment of mild to moderate
eczema (atopic dermatitis) in patients ≥ 2 yo
• Dose: apply a thin layer of ointment twice
daily
• ADE: application site pain, hypersensitivity
reaction
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533371.htm